Compare · MDLN vs XENT
MDLN vs XENT
Side-by-side comparison of Medline Inc. (MDLN) and Intersect ENT Inc. (XENT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and XENT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $50.91B, about 55.9x XENT ($911.2M).
- MDLN has hit the wire 4 times in the past 4 weeks while XENT has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 5 for XENT).
- Company
- Medline Inc.
- Intersect ENT Inc.
- Price
- $38.78+3.02%
- $28.25+0.02%
- Market cap
- $50.91B
- $911.2M
- 1M return
- +7.57%
- -
- 1Y return
- -4.83%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2014
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 5
Intersect ENT Inc.
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.
Latest MDLN
- Medline strengthens California distribution network with new 1 million-square-foot facility in Perris
- Medline Inc. filed SEC Form 8-K: Leadership Update
- Medline announces Prime Vendor agreement with Allina Health
- Securing new 1.6-plus million square feet of new space after fire, Medline leases two large distribution centers in Northern California
- Medline to report second quarter 2026 results on August 5, 2026
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
Latest XENT
- FDA Approval for SINUVA issued to INTERSECT ENT INC
- SEC Form POSASR filed by Intersect ENT Inc.
- SEC Form RW WD filed by Intersect ENT Inc.
- Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
- SEC Form 15-12B filed by Intersect ENT Inc.
- SEC Form S-8 POS filed by Intersect ENT Inc.
- SEC Form EFFECT filed by Intersect ENT Inc.
- SEC Form 4 filed by Hattangadi Neil A
- SEC Form 4: Meier Richard A closing all direct ownership in the company
- SEC Form 4: Fernandez Reyna M closing all direct ownership in the company